Contrasting Connect Biopharma (NASDAQ:CNTB) and GRAIL (NASDAQ:GRAL)

GRAIL (NASDAQ:GRAL) and Connect Biopharma (NASDAQ:CNTB) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Insider and Institutional Ownership

58.7% of Connect Biopharma shares are owned by institutional investors. 1.8% of GRAIL shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares GRAIL and Connect Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Connect Biopharma	N/A	-165.41%	-121.58%

Analyst Ratings

This is a breakdown of current ratings and target prices for GRAIL and Connect Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1	6	5	0	2.33
Connect Biopharma	1	0	8	0	2.78

GRAIL currently has a consensus price target of $119.80, suggesting a potential downside of 16.47%. Connect Biopharma has a consensus price target of $5.88, suggesting a potential upside of 632.36%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than GRAIL.

Volatility & Risk

GRAIL has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500.

Valuation and Earnings

This table compares GRAIL and Connect Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$165.26 million	38.77	-$408.35 million	($9.75)	-14.71
Connect Biopharma	$2.95 million	17.11	-$55.48 million	($1.19)	-0.67

Connect Biopharma has lower revenue, but higher earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Connect Biopharma beats GRAIL on 9 of the 14 factors compared between the two stocks.

About GRAIL

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.